He Xi, Li Guohong, Huang Letao, Shi Haixing, Zhong Sha, Zhao Siyu, Jiao Xiangyu, Xin Jinxiu, Yin Xiaoling, Liu Shengbin, He Zhongshan, Guo Mengran, Yang Chunli, Jin Zhaohui, Guo Jun, Song Xiangrong
Department of Critical Care Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan China.
State Key Laboratory of Quality Research in Chinese Medicine Macau Institute for Applied Research in Medicine and Health Macau University of Science and Technology Taipa Macau China.
MedComm (2020). 2025 Jan 2;6(1):e70035. doi: 10.1002/mco2.70035. eCollection 2025 Jan.
Messenger RNA (mRNA) therapeutics have garnered considerable attention due to their remarkable efficacy in the treatment of various diseases. The COVID-19 mRNA vaccine and RSV mRNA vaccine have been approved on the market. Due to the inherent nuclease-instability and negative charge of mRNA, delivery systems are developed to protect the mRNA from degradation and facilitate its crossing cell membrane to express functional proteins or peptides in the cytoplasm. However, the deficiency in transfection efficiency and targeted biological distribution are still the major challenges for the mRNA delivery systems. In this review, we first described the physiological barriers in the process of mRNA delivery and then discussed the design approach and recent advances in mRNA delivery systems with an emphasis on their tissue/cell-targeted abilities. Finally, we pointed out the existing challenges and future directions with deep insights into the design of efficient mRNA delivery systems. We believe that a high-precision targeted delivery system can greatly improve the therapeutic effects and bio-safety of mRNA therapeutics and accelerate their clinical transformations. This review may provide a new direction for the design of mRNA delivery systems and serve as a useful guide for researchers who are looking for a suitable mRNA delivery system.
信使核糖核酸(mRNA)疗法因其在多种疾病治疗中显著的疗效而备受关注。新冠mRNA疫苗和呼吸道合胞病毒(RSV)mRNA疫苗已获批准上市。由于mRNA固有的核酸酶不稳定性和负电荷特性,人们开发了递送系统来保护mRNA不被降解,并促进其穿过细胞膜在细胞质中表达功能性蛋白质或肽。然而,转染效率和靶向生物分布方面的不足仍是mRNA递送系统面临的主要挑战。在这篇综述中,我们首先描述了mRNA递送过程中的生理屏障,然后讨论了mRNA递送系统的设计方法和最新进展,重点是它们的组织/细胞靶向能力。最后,我们指出了现有挑战和未来方向,并对高效mRNA递送系统的设计进行了深入探讨。我们相信,高精度靶向递送系统能够极大地提高mRNA疗法的治疗效果和生物安全性,并加速其临床转化。这篇综述可能为mRNA递送系统的设计提供新方向,并为寻求合适mRNA递送系统的研究人员提供有用的指导。
MedComm (2020). 2025-1-2
J Mater Chem B. 2023-3-8
Acc Chem Res. 2011-8-26
Explor Target Antitumor Ther. 2022
Acc Chem Res. 2012-3-28
Acc Chem Res. 2012-3-19
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023-8-25
Biol Proced Online. 2025-6-3
Biomaterials. 2025-3
J Mater Chem B. 2024-8-22
Adv Sci (Weinh). 2024-9
Mater Today Bio. 2024-5-29
Nat Commun. 2024-5-22